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ABSTRAK
Adenoma hepatoselular merupakan tumor jinak hati yang sangat jarang, dengan predominasi pada wanita 
usia muda. Estimasi insidens 3-4 kasus per 1.000.000 populasi setiap tahunnya menjadikan kondisi ini memiliki 
tantangan diagnostik tersendiri. Melalui naskah ini kami melaporkan seorang wanita berusia 30 tahun dengan 
adenoma hepatoselular tanpa faktor risiko klasik. Rangkaian metode diagnostik telah dikerjakan untuk dapat 
menegakkan diagnosis dan hanya biopsi eksisi dari reseksi segmental yang menunjukkan kemaknaan nilai 
diagnostik. Kasus ini mengilustrasikan peran dari pulasan imunohistokimia pada biopsi eksisi sebagai modalitas 
diagnostik terbaik untuk adenoma hepatoselular, sekaligus sebagai modalitas terapeutik untuk mencegah 
transformasi keganasan.
Kata kunci: adenoma hati, tumor jinak hati, diagnosis, penanda imunohistokimia, reseksi.
ABSTRACT
Hepatocellular adenoma is an extremely rare benign tumor of the liver which predominantly in young 
women. Its rare incidence with estimated 3-4 cases per 1.000.000 annually makes it a diagnostic challenge. 
Here we present a 30-year-old female patient with hepatocellular adenoma without classic risk factors. A 
series of work up tools have been performed in order to diagnose the condition. None but excision biopsy 
from segmental resection had been showed to increase diagnostic confidence. This case illustrates the role of 
immunohistochemical staining from excision biopsy as the best diagnostic modality of hepatocellular adenoma 
as well as therapeutic modality to prevent malignant transformation.
Keywords: liver adenoma, benign liver tumor, diagnosis, immunohistochemical marker, resection.
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INTRODUCTION
Hepatocellular adenoma (HCA), also 
known as hepatic adenoma, are rare, benign, 
hormonal induced hepatic tumors. Commonly 
found in childbearing-aged women, HCA 
has been strongly correlated with the use of 
oral contraceptives.1 Incidence of HCA is 
approximately 1/1.000.000 in women without 
history of oral contraceptives compare to 30-
40/1.000.000 in long-term users.2,3 Nevertheless, 
the mechanism of estrogen-induced HCA is 
not completely understood. Other etiologies 
inducing the development of HCA include long-
term use of anabolic androgenic steroids and 
glycogen storage diseases.4
The clinical presentation of hepatic adenomas 
varies widely. About 25-50% patients with hepatic 
adenomas reported with pain in the right upper 
quadrant or epigastric region. Lesions may be 
palpable or incidentally found during abdominal 
imaging study for other study. Bordeaux 
classification of hepatic adenomas is currently 
being evaluated. The classification consists of 
hepatocyte nuclear factor 1α-inactivated HCA 
(HNF1α HCA 30-35%), β cateninmutated HCA 
(β-cat HCA 10-15%), inflammatory HCA (50%), 
and a subgroup of less than 10% that remains 
unclassified.5
Basically, HCA is diagnosis made by excluding 
other differential diagnosis. Serological test are 
performed to exclude other possible diagnosis. 
Serum aminotransferase levels may be mildly 
elevated due to the mass effect of the tumor. Most 
patients with hepatic adenoma have normal range 
of serum alpha-fetoprotein (AFP). An elevation in 
AFP levels is correlated with primary carcinoma or 
malignant transformation of adenoma. Radiologic 
findings are nondiagnostic because the mass 
commonly found in solitary and well demarcated 
lesion. Advances in contrast-enhanced MRI 
and contrast-enhanced ultrasonography may 
be helpful to distinguish hepatic adenoma and 
possibly determined Bordeaux classification 
subtypes.6 Immunohistochemistry may be 
performed to further characterize lesion under 
the new Bordeaux classification while results 
of histologic evaluation with liver biopsy are 
nondiagnostic and insensitive.5 The prognostic 
for hepatic adenoma is not well established. 
While complete resolution is uncommon, the risk 
of malignant transformation still remains even 
after oral contraceptive or steroid use has been 
discontinued. All symptomatic tumors should 
be resected. Asymptomatic adenomas smaller 
than 5 cm in size may be managed with close 
monitoring.7
CASE ILLUSTRATION
A 30-year-old female was referred with 
abdominal pain in the right upper quadrant over 
the preceding one year. The pain was described 
as localized, episodic, and non-triggered by food 
or activity. She had not complained of nausea, 
vomit, dark-colored stool urine, black stool, 
abdominal enlargement, bloating or weight loss. 
She could still carry on daily activity without 
restriction. She had no history of jaundice, 
blood transfusions, hepatitis, excessive alcohol 
consumption, or long-term oral contraception. 
Clinical examination revealed no abnormalities, 
no abdominal palpable mass found.
Laboratory tests were within normal limits. 
Tests for hepatitis B surface antigen and hepatitis 
C antibodies were all non-reactive. Serum tumor 
markers (AFP, CEA, Ca 19-9, Ca 125) were all 
within normal range. Multiphase abdominal multi 
slice computed tomography (MSCT) showed a 
focal mass in right lobe liver, segment 5, with size 
of 6.3 cm x 5.2 cm x 5 cm. The mass was shown 
as iso-hypodense lesion with slight enhancement 
in arterial phase, followed by heterogeneous 
enhancement in portovenous phase and contrast 
washed out in delayed phase (Figure 1). 
The CT findings suggested hepatocellular 
carcinoma with differential diagnosis of 
adenoma, adenocarcinoma. Liver core biopsy 
was then performed to ensure the diagnosis. Core 
biopsy findings suggested liver adenoma with 
differential diagnosis hepatocellular carcinoma 
grade 1. Immunohystochemical staining was 
performed following core biopsy, with findings 
of positive granular cytoplasm with expression 
of glypican 3, complete expression of CD 34, 
positive expression of CD10, and less than 5% 
of expression of Ki67 (Figure 2). The findings 
suggested hepatocellular carcinoma grade 1.
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The patient underwent open laparotomy. 
Medial laparotomy incision from xiphoid process 
to two fingers below umbilicus, passing through 
cutis, sub cutis, and linea alba. Intraoperative 
ultrasonography (USG) was performed and 
showed solid lesion of 3 x 3 x 3 cm in hepatic 
segment V. Tumor resection margins were 
determined with the use of USG guidance. Liver 
mobilization began by releasing the liver from 
the falciform ligament, coronary ligament, and 
triangular ligament. Hepatoduodenal ligament 
was identified and released from surrounding 
tissues at right hepatic artery, right portal vein 
and common bile duct using Pringle maneuver. 
To treat the lesion, hepatectomy of segment V 
was performed.
The specimen was brown-black colored, 
spongy, measuring 10 x 7 x 4.5 cm. The mass 
itself measured 7 x 6 x 3 cm, yellow-brown 
colored, firm and tender. A 2.5 x 2 x 1.5 cm 
hollow with inner irregular surface was shown 
in division of the mass (Figure 3). Microscopic 
examination showed tumor tissues with partly 
poor-circumscribed edges. Neovascularization 
was also seen. Tumor cells showed hepatocytes 
differentiation consists of trabecular tissue of 2-4 
cells/field in depth, common uniform nucleated 
tumor cells, some with vivid nucleolus, and 
mitosis was hardly found (Figure 4). Microscopic 
examination showed the lesion was hepatocellular 
adenoma. The specimen was consulted and sent 
to Groningen, Netherlands and New York, USA, 
of which both confirmed the diagnosis was 
hepatocellular adenoma. Mutation examination 
revealed it was inactivated hepatocellular 
adenoma through evaluation of HNF-1α.
Figure 1. Multiphase abdominal MSCT of the patient 
(clockwise from top left): non-contrast, arterial phase, venous 
phase, delayed phase.
Figure 2. Histopathology finding and immunohistochemical 
staining on core biopsy specimen (clockwise from top left): 
stained with Hematoxylin & Eosin (H&E), CD34, glypican-3, 
and Ki67.
Figure 3. Macroscopic specimen of liver mass.
Figure 4. H&E staining on excision biopsy specimen 
showing hepatocellular adenoma characterized by sinusoidal 
dilatation and cluster of small arteries surrounded by 
inflammation.
No signs of liver failure were shown after 
surgery. The patient was discharged one week 
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after surgery. The patient was advised for follow-
up ultrasound examination six months after the 
operation.
DISCUSSION
The differential diagnosis of benign liver 
cell  tumors requires understanding of the 
clinical, radiological, and pathological features 
of the liver lesions. A detailed history, physical 
examinations, hepatic tests, imaging, and 
histopathological studies are necessary for 
precise diagnosis. There are several points of 
approach for the lesion which may be beneficial 
as the clues of establishing HCA diagnosis, 
differentiating it with focal nodular hyperplasia 
(FNH) or hepatocellular carcinoma (HCC).
Patients with liver adenomatosis range in 
age from 12 to 75 years, with a mean age of 34 
years.8 Eighty-eight percent of them are women, 
as well as those with FNH (80-90%), meanwhile 
HCC predominates in men.9 Patients diagnosed 
with HCA are typically young women with long-
standing oral contraceptive use or with history of 
glycogen storage diseases.9 In the present case, 
the diagnosis is difficult to be determined and 
distinguished from other possible diagnosis due 
to absence of classic risk factors from neither 
HCA nor HCC (viral, alcoholic, metabolic 
syndrome) and FNH (local or systemic vascular 
anomalies). HCA typically occurs in noncirrhotic 
livers.8 However, a recent case of HCA was 
observed in a hepatitis B virus or alcoholic-
associated cirrhotic liver.10
The majority of the tumors are in the size 
range of 5 to 15 cm at the time diagnosis, but they 
can be < 0,5 or > 30 cm. Clinical presentation is 
usually related to the size of the tumors, with size 
of ≥ 5 cm tend to be more likely simptomatic, 
presented with acute abdominal pain (43%) and 
hemorrhagic complications (46%).8
 Several diagnostic modalities have been 
performed. Unlike in HCC, both HCA and FNH 
were usually presented with normal function 
liver test results and no or minimal elevation in 
serum tumor markers, such as α-fetoprotein.10 
Although the laboratory test results in our case 
appeared within normal range, hepatocellular 
carcinoma was suggested from radiologic 
findings.
Radiological findings for HCA are similar 
with those in HCC or FNH. Adenomas are 
sharply marginated (85%), nonlobulated (95%), 
sometimes encapsulated (30%), and rarely 
calcified (10%), demonstrated with homogenous 
or nearly homogenous enhancement in 80% of 
cases.11 While most of adenomas were presented 
in a single mass that may contain area of fat or 
hemorrhage, we have found none in our case. 
Also, the accurate differentation of the HCA 
lesion often can be better interpreted with 
magnetic resonance imaging (MRI) or contrast 
enhanced ultrasonography (CEUS).8,9
S e v e r a l  p r i m a r y  h e p a t i c  t u m o r s , 
including HCC, FNH and HCA, are classified 
as hypervascular tumors, on the basis of 
helical multiphasic CT observations and 
pathophysiology, and therefore a confident 
preoperative diagnosis of HCA are difficult 
based on the radiologic observations.12,13 FNH 
usually comes with diagnostic pointer of central 
scar with centrifugal or eccentric enhancement,8 
whereas well-differentiated HCC is usually large, 
heterogenous, and lobulated, with large, central, 
or eccentric scars and radiating fibrous septa, 
calcifications (40-68%), as well as abdominal 
lymphadenopathy (65%).11
Distinction between HCA and HCC are 
obviously of paramount clinical importance in 
determining appropriate therapy and assessing 
prognosis, unless often can usually be achieved 
only on histologic grounds. We found that the 
histopathology examination of core biopsy from 
our patient indicated benign lesion. The later 
immunohistochemical staining with glypican 
3, CD34, CD10 and Ki67 of core biopsy 
specimen indicated HCC lesion. However, 
distinguishing HCA from well-differentiated 
HCC can be extremely challenging when the 
diagnostic material is a small needle biopsy.8 
Nonetheless, the efficacy of percutaneous liver 
biopsy is limited with preoperative accuracy 
about 50%.13,14
Conservative treatment was the initial 
treatment for HCA < 5 cm in diameter. A tumor 
size ≥ 5 cm and abdominal complaints, as found 
in our case, were major criteria for surgical 
resection. Among all HCAs, 9% may transform 
into HCC with risk factors including male sex, 
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androgen use, size ≥ 5 cm, and ß-catenin-mutated 
HCA. In these complicated cases, early surgical 
removal may improve patient outcomes.15 As an 
alternative, several reports also demonstrated 
the efficacy of radiofrequency ablation (RFA), 
especially in cases not amenable to surgery or 
in patients who would require major hepatic 
resection otherwise.16 Our patient was then 
decided to undergone surgery with hepatectomy 
for diagnostic and therapeutic purpose.
Immunohistochemical examination of 
glutamine synthetase, beta-catenin, serum 
amyloid A and C-reactive protein, and liver 
fatty-acid binding protein on surgical specimen 
determined the lesion as of non-inflammatory 
HCA or specifically HNF-1α HCA. Among all 
HCAs, the HNF-1α HCA is the least aggressive 
subtype with almost no risk for the development 
of malignancy.
CONCLUSION
As illustrated in this case, similar findings 
of HCA and well-differentiated HCC as well as 
FNH in radiologic findings can be a challenge 
in distinguishing the diagnosis. Because 
management of these tumors is different, 
confident preoperative diagnosis is essential. 
Although documented in low statistic number, 
HCA could occur in individual without classic risk 
factor. Atypical features such as heterogeneous 
enhancement should be evaluated with additional 
imaging, such as MRI; or biopsy; even surgical 
resection. In such cases, all possible diagnosis 
must be excluded. Resection and histopathology 
examination remains the best modality in 
diagnosing HCA, as well as therapeutic option 
to exclude malignant neoplasm.
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